These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9004064)

  • 21. Pruritus induced by interruption of paroxetine therapy.
    Mazzatenta C; Peonia G; Martini P
    Br J Dermatol; 2004 Apr; 150(4):787. PubMed ID: 15099390
    [No Abstract]   [Full Text] [Related]  

  • 22. Should paroxetine be used to treat depression during pregnancy?
    Mintzes B; Jureidini J
    Am J Psychiatry; 2008 Nov; 165(11):1487; author reply 1487-8. PubMed ID: 18981077
    [No Abstract]   [Full Text] [Related]  

  • 23. Antidepressant-related hypomania in a patient with premenstrual dysphoric disorder.
    Hsiao MC; Liu CY
    J Clin Psychopharmacol; 2002 Oct; 22(5):534-5. PubMed ID: 12352284
    [No Abstract]   [Full Text] [Related]  

  • 24. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine in the treatment of resistant depression.
    Caetano D; Caetano SC
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract]   [Full Text] [Related]  

  • 26. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient.
    Liau CH; Shen WW; Su KP
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):121-2. PubMed ID: 16472373
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment.
    Pollock BG; Laghrissi-Thode F; Wagner WR
    J Clin Psychopharmacol; 2000 Apr; 20(2):137-40. PubMed ID: 10770450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bupropion-induced hypomania in a patient with unipolar depression.
    Hussain H; Butt MA
    Aust N Z J Psychiatry; 2008 Aug; 42(8):746. PubMed ID: 18622783
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine-imipramine interaction.
    Leroi I; Walentynowicz MA
    Can J Psychiatry; 1996 Jun; 41(5):318-9. PubMed ID: 8793156
    [No Abstract]   [Full Text] [Related]  

  • 33. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
    Rapaport MH; Lydiard RB; Pitts CD; Schaefer D; Bartolic EI; Iyengar M; Carfagno M; Lipschitz A
    J Clin Psychiatry; 2009 Jan; 70(1):46-57. PubMed ID: 19026248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nocturnal enuresis after paroxetine abrupt discontinuation: a case report.
    Polimeni G; Grugno R; Cordici F; Vitetta A; Caputi AP; Bramanti P
    J Clin Psychopharmacol; 2008 Oct; 28(5):589-91. PubMed ID: 18794668
    [No Abstract]   [Full Text] [Related]  

  • 35. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
    Yasui-Furukori N; Kaneko S
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentation of paroxetine with clocapramine in panic disorder.
    Saito M; Miyaoka H
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):449. PubMed ID: 17610675
    [No Abstract]   [Full Text] [Related]  

  • 37. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
    Chuang YF; Chiu YL; Hwang TJ; Chu TS
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
    [No Abstract]   [Full Text] [Related]  

  • 38. Paroxetine in child and adolescent outpatients with panic disorder.
    Masi G; Toni C; Mucci M; Millepiedi S; Mata B; Perugi G
    J Child Adolesc Psychopharmacol; 2001; 11(2):151-7. PubMed ID: 11436954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind pilot trial of desipramine versus fluoxetine in panic patients.
    Bystritsky A; Rosen RM; Murphy KJ; Bohn P; Keys SA; Vapnik T
    Anxiety; 1994-1995; 1(6):287-90. PubMed ID: 9160589
    [No Abstract]   [Full Text] [Related]  

  • 40. [Possible serotoninergic syndrome associated with coadministration of paroxetine and tramadol].
    Llinares-Tello F; Escrivá-Moscardó S; Martínez-Pastor F; Martínez-Mascaraque P
    Med Clin (Barc); 2007 Mar; 128(11):438. PubMed ID: 17394862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.